Analysis shows improved medication adherence in Medicare beneficiaries, suggesting positive implications for health outcomes.
In this difference-in-differences analysis, the IRA's 2024 prescription drug provisions were associated with a reduction in cost-related medication nonadherence among eligible Medicare beneficiaries in their first year. These early improvements may have important implications for chronic disease management and downstream clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Marinacci et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: